Trial · NCT07585136
Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders
NCT07585136, Phase 1, Recruiting, St. Jude Children's Research Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders. Trials, record NCT07585136. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07585136
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders
- NCT number
- NCT07585136
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 12 participants, estimated
- Lead sponsor
- St. Jude Children's Research Hospital
- Conditions
- Bone Marrow Failure Syndrome
- Interventions
- Filgrastim, Plerixafor, Leukapheresis
- First posted
- 2026-05-13
- Last updated
- 2026-10-06
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of treatment-emergent adverse events following filgrastim plus plerixafor administration | From initiation of drug administration through Day +7 to +10 follow-up | Safety will be assessed by the incidence, type, and severity of adverse events occurring after administration of filgrastim plus plerixafor in participants with bone marrow failure syndromes. |
| Secondary | Number of participants achieving peripheral blood CD34+ counts ≥5 cells/µL | From initiation of plerixafor administration through completion of apheresis, or 6 hours after drug administration if apheresis is not performed | Feasibility of hematopoietic stem and progenitor cell mobilization will be assessed by peripheral blood CD34+ cell counts measured after plerixafor administration and prior to or during apheresis. |
| Secondary | Peripheral blood CD34+ kinetics following filgrastim plus plerixafor administration | After plerixafor administration through completion of apheresis, or 6 hours after drug administration if apheresis is not performed | Peripheral blood CD34+ cell counts will be measured after plerixafor administration and prior to or during apheresis. |
| Secondary | Observed CD34+ cell yield after 1 blood volume apheresis | At completion of 1 blood volume apheresis on Day 5 | CD34+ cell yield (CD34+ cells/kg) collected after processing 1 blood volume during apheresis following filgrastim plus plerixafor administration. |
| Secondary | Estimated total CD34+ cell yield from projected full-volume apheresis | At completion of 1 blood volume apheresis on Day 5 | Estimated total CD34+ cell yield (CD34+ cells/kg) projected from the observed yield after processing 1 blood volume during apheresis. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07585136
GET https://conductscience.org/api/trials/v1/NCT07585136/registered